The final, formatted version of the article will be published soon.
REVIEW article
Front. Med.
Sec. Gene and Cell Therapy
Volume 11 - 2024 |
doi: 10.3389/fmed.2024.1418786
Nanogene Editing Drug Delivery Systems in the Treatment of Liver Fibrosis
Provisionally accepted- 1 College of Pharmacy and Chemistry & Chemical Engineering, Taizhou University, Taizhou, China
- 2 Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
- 3 Department of International Medicine, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China
Liver fibrosis is a group of diseases that seriously affect the health of the world's population. Despite significant progress in understanding the mechanisms of liver fibrogenesis, the technologies and drugs used to treat liver fibrosis have limited efficacy. As a revolutionary genetic tool, gene editing technology brings new hope for treating liver fibrosis. Combining nano-delivery systems with gene editing tools to achieve precise delivery and efficient expression of gene editing tools that can be used to treat liver fibrosis has become a rapidly developing field. This review provides a comprehensive overview of the principles and methods of gene editing technology and commonly used gene editing targets for liver fibrosis. We also discuss recent advances in common gene editing delivery vehicles and nano-delivery formulations in liver fibrosis research. Although gene editing technology has potential advantages in liver fibrosis, it still faces some challenges regarding delivery efficiency, specificity, and safety. Future studies need to address these issues further to explore the potential and application of liver fibrosis technologies in treating liver fibrosis.
Keywords: gene editing, delivery system, liver fibrosis, CRISPR-Cas9, Nanoparticles, targeted therapy
Received: 17 Apr 2024; Accepted: 09 Sep 2024.
Copyright: © 2024 JI, Li, Wang, Jia, Chen, Jiang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Qun Wang, College of Pharmacy and Chemistry & Chemical Engineering, Taizhou University, Taizhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.